Surgical Adjuvant Therapy of Non-Small-Cell Lung Cancer

  • E. Carmack Holmes
Part of the Cancer Treatment and Research book series (CTAR, volume 45)

Abstract

Lung cancer is the leading cancer killer in the United States. One hundred forty thousand patients will develop lung cancer annually, and half of these patients will have disease confined to the thorax without clinical evidence of dissemination (figure 14.1). About 20% will have stage I disease, 30% will have more advanced local disease, some of whom can be resected surgically with a low expectation of cure, and others with tumor localized to the thorax will be technically unresectable. Surgery alone can cure most patients with T1N0 lesions, and about 60% of the patients with T2N0 and T1N1 tumors can be cured by surgical resection. Surgical treatment alone cures about half the patients with T2N1 squamous disease, and only 25% of the patients with T2N1 adenocarcinoma. A subset of patients with T3N2 disease can expect a favorable survival following surgical resection, but most patients in this category have technically unresectable disease (table 14.1) [1].

Keywords

Toxicity Urea Platinum Adenocarcinoma Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mountain CF, Lukeman JM, Hammar SP, et al: Lung cancer classification: The relationship of disease extent and cell type to survival in a clinical trials population. J Surg Oncol 35:147–156, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Feld R, Rubinstein LV, Weisenburger TH: The Lung Cancer Study Group: Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 2:1352–1357, 1984.PubMedGoogle Scholar
  3. 3.
    Shields TM, Robinette CD, Keehn MS: Bronchial carcinoma treated by adjuvant cancer chemotherapy. Arch Surg 109:329–333, 1974.PubMedGoogle Scholar
  4. 4.
    Slack HH: Bronchogenic carcinoma: nitrogen mustard as a surgical adjunct and factors influencing survival. University Surgical Adjuvant Lung Cancer Project. Cancer 25:987–1002, 1970.PubMedCrossRefGoogle Scholar
  5. 5.
    Brunner KW, Marthaler T, Muller W: Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma. Cancer Chemother Rep 4:125–132, 1973.Google Scholar
  6. 6.
    Shields TM, Higgins GA, Humphrey EW, Matthews M, Kuhu RG: Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung. Cancer 50:1713–1721, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    The Lung Cancer Study Group (prepared by Lad T, Rubenstein L, Sadeghi A): The benefit of adjuvant treatment for resected local advanced non-small-cell lung cancer. J Clin Oncol 6:9–17, 1988.Google Scholar
  8. 8.
    Henderson IC: Adjuvant systemic therapy for early breast cancer. In: Haskell CM (ed): Current Problems in Cancer, Volume 9. 1987.Google Scholar
  9. 9.
    The Lung Cancer Study Group (prepared by Weisenburger TH, Gail M): Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid carcinoma of the lung. N Engl J Med 315:1377–1381, 1986.CrossRefGoogle Scholar
  10. 10.
    Rosen G, Caparros B, Huevos A, et al: Preoperative chemotherapy for osteosarcoma: Selection of postoperative chemotherapy based on the response of the primary tumor to chemotherapy. Cancer 49:1221–1230, 1982.PubMedCrossRefGoogle Scholar
  11. 11.
    Eilber FR, Morton DL, Eckardt J, et al: Limb salvage for skeletal and soft tissue sarcomas: Multidisciplinary preoperative therapy. Cancer 53:2574–2584, 1984.CrossRefGoogle Scholar
  12. 12.
    Greist A, Roth B, Einhorn L, et al: Cis-platinum combination chemotherapy for disseminated germ cell tumors: Long term follow-up. Proc Am Soc Clin Oncol 4:100 (Abst C-388), 1985.Google Scholar
  13. 13.
    Fram R, Skarin A, Balikian J, et al: Combination chemotherapy followed by radiation therapy in patients with regional stage III unresectable non-small cell cancer. Cancer Treat Rep 69:587–590, 1985.PubMedGoogle Scholar
  14. 14.
    The Lung Cancer Study Group (prepared by Eagan RT, Ruud C, Lee R, Pairolero P, Gail M): A pilot study of induction therapy with cyclophosphamide, doxorubicin, cis-platinum (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small-cell lung cancer. Cancer Treat Rep 71:895–900, 1987.PubMedGoogle Scholar
  15. 15.
    Taylor SG, Trybula M, Bonomi PD, Faber LP, et al: Simultaneous Cisplatin-Fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III non-small-cell lung cancer. Ann Thorac Surg 43:87–91, 1987.PubMedCrossRefGoogle Scholar
  16. 16.
    The Lung Cancer Study Group (prepared by Weiden P): Preoperative chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a phase II study of the Lung Cancer Study Group. Proc Am Soc Clin Oncol 6:185 (Abst 728), 1987.Google Scholar
  17. 17.
    Kris MG, Gralla RG, Martini N, Burke MT, McCormack P, Bains M, Kaiser L, Burt M, Heelan RT: Trial of preoperative Cisplatin plus vinca alkaloid chemotherapy in non-small-cell lung cancer (NSCLC) patients with clinically apparent, ipsilateral, mediastinal lymph node metastases. Proc Am Soc Clin Oncol 6:177 (Abst 697), 1987.Google Scholar
  18. 18.
    Overgaard J, Kahn AR: Selective enhancement of radiation response in a C3H mammary carcinoma by cis-platinum. Cancer 65:649, 1982.Google Scholar
  19. 19.
    Byfield JE, Stanton W, Sharp TR, et al: Phase I/II study of 120 hour infused 5-FU and split-course radiation therapy in localized non-small-cell lung cancer. Cancer Treat Rep 67:933, 1983.PubMedGoogle Scholar
  20. 20.
    Bonomi P, Sandler S, Bushy J, Reddy S: Adjuvant chemotherapy in locally advanced squamous cell bronchogenic carcinoma. Proc Am Soc Clin Oncol 3:228 (Abst C-892), 1984.Google Scholar

Copyright information

© Kluwer Academic Publishers, Boston 1989

Authors and Affiliations

  • E. Carmack Holmes

There are no affiliations available

Personalised recommendations